Zobrazeno 1 - 10
of 35
pro vyhledávání: ''
Publikováno v:
Journal of Oncology Pharmacy Practice. 28:232-236
Introduction The use of TKIs in CML has dramatically altered the natural course of the disease and improved outcomes for patients. TKIs overall have a very favorable safety profile. Dasatinib, a second generation TKI, is commonly used as a first-line
Autor:
Sandrine Combret, Aurélie Grandvuillemin, Charlène Boulay, Pauline Lory, Didier Mayeur, Antonin Schmitt, Nils Martin, Jeffrey Lombardi
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:2041-2044
Introduction Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate which combine trastuzumab (T), a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), and a cytotoxic molecule derived from maytansine (DM1). Case
Autor:
Lucrezia Raimondi, Filippo Maria Raimondi, Luigi Rossi, Rachele Lazzeroni, Marta Pietranera, Laura Di Benedetto, Elisa Gozzi, Gian Paolo Spinelli
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:1542-1547
Introduction Gemcitabine is a nucleoside analog and pyrimidine antimetabolite that inhibits RNA synthesis, currently approved for use to treat a variety of cancers, among which ovarian cancers. Gemcitabine is considered relatively safe and it is gene
Autor:
Julian Gratiaux, Laetitia Visseaux, Florian Slimano, Damien Botsen, Chloé Gossery, Olivier Bouché, Chirine Rezzag-Mahcene
Publikováno v:
Journal of Oncology Pharmacy Practice. 28:247-249
Introduction Capecitabine is an antimetabolite antineoplastic agent widely used in the treatment gastrointestinal cancers. The common frequently reported cutaneous adverse drug reaction associated with capecitabin are a palmar-plantar erythrodysesthe
Autor:
Fabio Gelsomino, Samantha Pozzi, Alessia Bari, Francesco Caputo, Massimo Dominici, Krisida Cerma, Martina Fanelli
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:766-770
Introduction Pazopanib, a tyrosine kinase inhibitor (TKI), is a standard treatment for various tumours, including metastatic non-adipocytic soft-tissue sarcomas. In literature, erythrocytosis has been described as a TKI-related condition. Case report
Autor:
Mark A Marinella
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:1482-1485
The ongoing pandemic caused by severe acute respiratory syndrome (SARS) coronavirus type 2 (SARS-CoV-2, also known as COVID-19) has caused unprecedented strain on the global healthcare system, causing thousands of deaths worldwide. Patients with unde
Publikováno v:
Journal of Oncology Pharmacy Practice
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors represent the standard of care in patients with EGFR mutation-positive ( EGFRm+) non-small cell lung cancer (NSCLC). The availability of several EGFR tyrosine kinase inhibitors approv
Autor:
Caitlin R. Rausch, Shilpa Paul
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:1220-1224
The advent of BCR–ABL1 tyrosine kinase inhibitors has revolutionized the treatment and prognosis of chronic myeloid leukemia. Life expectancy for patients with chronic phase chronic myeloid leukemia now nears that of the healthy population; however
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:1200-1212
Acute myeloid leukemia has recently undergone a significant transition into identifying and successfully inhibiting driver mutations leading to disease. One of the most common mutations in acute myeloid leukemia involves the protein FMS-like tyrosine
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:119-127
Introduction Methotrexate (MTX) is a cytotoxic antimetabolite. Intravenous (IV) hydration and urine alkalinization with sodium bicarbonate (NaHCO3) can mitigate nephrotoxicity associated with high-dose MTX (HDMTX, doses ≥500 mg/m2). A shortage of I